廣生堂(300436.SZ)及子公司共29個藥品納入國家醫保目錄 4個藥品退出
格隆匯8月22日丨廣生堂(300436.SZ)公佈,根據國家醫保局、人力資源社會保障部於2019年8月20日下發的《關於印發
<國家基本醫療保險、工傷保險和生育保險藥品目錄>
的通知》(醫保發〔2019〕46號,“國家醫保目錄”),公司及控股子公司江蘇中興藥業有限公司(“中興藥業”)共有29個藥品被納入國家醫保目錄,其中甲類15個,乙類14個。公司及中興藥業主要生產、銷售的8個藥品(合計銷售收入佔公司2018年度營業收入的97.17%)均被納入。
國家基本醫療保險、工傷保險和生育保險藥品目錄>
此次退出醫保目錄的藥品共4個:三七片(廣生堂)、曲匹布通(中興藥業)、複方地芬諾酯(中興藥業)、氯丙那林(中興藥業);醫保分類由乙類調整為甲類的藥品共2個:維生素B1(廣生堂)、維生素B6(廣生堂);以上6個藥品均不在產,此次調整對公司經營業績無影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.